UBS Group
CADL icon

UBS Group’s Candel Therapeutics CADL Stock Holding History

UBS Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
169,271
+19,416
+13% +$147K ﹤0.01% 5229
2026
Q1 		$734K Buy
149,855
+45,516
+44% +$248K ﹤0.01% 5783
2025
Q4 		$590K Buy
104,339
+10,268
+11% +$55.2K ﹤0.01% 5974
2025
Q3 		$480K Buy
94,071
+11,904
+14% +$68.8K ﹤0.01% 6122
2025
Q2 		$416K Sell
82,167
-104,927
-56% -$540K ﹤0.01% 6161
2025
Q1 		$1.06M Buy
187,094
+30,288
+19% +$247K ﹤0.01% 5248
2024
Q4 		$1.36M Buy
156,806
+147,360
+1,560% +$871K ﹤0.01% 5075
2024
Q3 		$65.5K Buy
9,446
+3,441
+57% +$21.4K ﹤0.01% 6650
2024
Q2 		$37.2K Buy
6,005
+5,995
+59,950% +$45K ﹤0.01% 6911
2024
Q1 		$16 Sell
10
-11,911
-100% -$17.7K ﹤0.01% 9056
2023
Q4 		$17.5K Buy
11,921
+11,911
+119,110% +$11.6K ﹤0.01% 7183
2023
Q3 		$9 Hold
10
– – ﹤0.01% 9226
2023
Q2 		$13 Hold
10
– – ﹤0.01% 8717
2023
Q1 		$14 Sell
10
-785
-99% -$1.53K ﹤0.01% 9444
2022
Q4 		$1.42K Sell
795
-3,386
-81% -$6.7K ﹤0.01% 9874
2022
Q3 		$13K Buy
4,181
+374
+10% +$1.27K ﹤0.01% 8009
2022
Q2 		$12K Buy
3,807
+1,807
+90% +$7.24K ﹤0.01% 7637
2022
Q1 		$10K Sell
2,000
-2,447
-55% -$12.2K ﹤0.01% 8397
2021
Q4 		$34K Buy
4,447
+1,447
+48% +$14K ﹤0.01% 7255
2021
Q3 		$33K Buy
+3,000
New +$24.9K ﹤0.01% 6662

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group's CADL Position: Q2 2026 in Review

UBS Group increased its Candel Therapeutics (CADL) stake by 13% in Q2 2026, buying an estimated $147K and bringing the position to 169,271 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #5229.

UBS Group first reported a position in CADL in Q3 2021 and has held it in 20 quarters since. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • UBS Group held 169,271 shares of Candel Therapeutics worth $1.74M as of Q2 2026.
  • UBS Group bought 19,416 Candel Therapeutics shares in Q2 2026, an estimated $147K.
  • Candel Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5229 holding.
  • UBS Group first reported a position in Candel Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.